Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Deep sequencing analysis of clinical samples from patients with acute infectious conjunctivitis during the COVID-19 delta surge in Madurai, India

Prajna Lalitha\textsuperscript{a}, N Venkatesh Prajna\textsuperscript{a}, Rameshkumar Gunasekaran\textsuperscript{a}, Gonugunta Vishnu Teja\textsuperscript{a}, Sankalp S. Sharma\textsuperscript{a}, Armin Hinterwirth\textsuperscript{b}, Kevin Ruder\textsuperscript{b}, Lina Zhong\textsuperscript{b}, Cindi Chen\textsuperscript{b}, Michael Deiner\textsuperscript{c}, ChunHong Huang\textsuperscript{d}, Benjamin A. Pinsky\textsuperscript{d,e}, Thomas M. Lietman\textsuperscript{b,c}, Thuy Doan\textsuperscript{b,c,*}, Gerami D. Seitzman\textsuperscript{b,c}, on behalf of the SCORPIO (Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes) Study Group

\textsuperscript{a} Aravind Eye Hospital, Madurai, India
\textsuperscript{b} Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA, United States
\textsuperscript{c} Department of Ophthalmology, University of California, San Francisco, CA, United States
\textsuperscript{d} Department of Pathology, Stanford University School of Medicine, Stanford, CA, United States
\textsuperscript{e} Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, United States

A B S T R A C T

Background: Seasonal outbreaks of infectious conjunctivitis remain a public health issue. Determination of outbreak etiologies in the context of a worldwide pandemic may provide useful information to guide public health strategies. The aim of this study was to identify pathogens associated with outpatient infectious conjunctivitis during the COVID-19 Delta surge.

Methods: This prospective study was conducted from April 2021 to September 2021. All outpatients presenting to the Aravind Eye Center (Madurai, India) with signs and symptoms consistent with acute infectious conjunctivitis were eligible. Three swabs were obtained from each participant: one from each conjunctiva and one from the anterior nares. Samples were processed for metagenomic RNA deep sequencing (RNA-seq).

Results: Samples from 106 study participants were sequenced. The most common presenting symptoms were tearing (86%) and itching (71%). Preauricular lymphadenopathy was present in 38% of participants. 20% of participants had close contacts with similar symptoms. Systemic symptoms such as coughing, runny nose, vomiting or diarrhea were uncommonly reported. 60% of all participants used some medicated eye drops upon enrollment. 75% of study participants demonstrated infection with human adenovirus D (HAdV-D). 11% of conjunctivitis was associated with SARS-CoV-2. 15% had no definitive pathogen detected. 8% of all participants had codetection of more than one pathogen on RNA-seq.

Conclusions: During the COVID-19 Delta surge in India, HAdV-D was the most common pathogen associated with infectious conjunctivitis. SARS-CoV-2 was the second most common associated pathogen. Seasonal surveillance may be necessary for the determination of emerging and reemerging pathogens responsible for infectious conjunctivitis.

1. Introduction

Worldwide epidemics of infectious conjunctivitis occur regularly [1, 2]. Episodes of infectious conjunctivitis continued despite the widespread implementation of nonpharmaceutical interventions designed to mitigate the COVID-19 pandemic, such as mask-wearing, hand-washing, and social distancing. We know infectious conjunctivitis etiology varies by location and season [3]. Pathogens driving infectious conjunctivitis during a COVID-19 pandemic have not been studied in a prospective manner.

As worldwide interest in emerging infectious disease increases, our collective ability to rapidly screen for and diagnose etiologies of any contagious process has wide reaching implications. SCORPIO (Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes) is a UCSF based international study aimed to determine the causes of infectious conjunctivitis worldwide. The Aravind Eye Hospital in Madurai, India, is one of the participating sites. This manuscript describes the pathogens responsible for infectious conjunctivitis during the COVID-19 Delta surge in Madurai, India, as determined by metagenomic RNA deep sequencing analysis (RNA-seq). A companion paper in this issue provides more details on the patients presenting specifically with SARS-CoV-2 conjunctivitis [4].

* Corresponding author.
E-mail address: thuy.doan@ucsf.edu (T. Doan).

https://doi.org/10.1016/j.jcv.2022.105318
Received 12 August 2022; Received in revised form 23 September 2022; Accepted 30 September 2022
Available online 5 October 2022
1386-6532/© 2022 Elsevier B.V. All rights reserved.
2. Materials & methods

This study adhered to the tenets of the Declaration of Helsinki. The Institutional Review Board of the University of California, San Francisco and Aravind Eye Hospital in Madurai, India, approved the study. Informed written consent was obtained from all patients. Guardians were consented for all children. Children older than 18 years of age provided assent. Conjunctival swabs were obtained from patients who presented to the Aravind Eye Hospital in Madurai from April 1 to May 1, 2021 and from June 1 to September 17, 2021. The gap in sample collection represented the lockdown period in which all research activities at Aravind were placed on-hold due to the Delta surge. Inclusion criteria required acute conjunctivitis symptoms for less than 14 days. Exclusion criteria were presumed allergic conjunctivitis or chemical conjunctivitis. Sterile polyester applicators (Puritan) were used to swab the lower conjunctival fornix of each eye. The most affected eye was swabbed first. A third swab of both nares was collected. All swabs were immediately placed in DNA/RNA-Shield (Zymo Research) and transferred to a −80°C freezer for long-term storage until tested. Details of sequencing, library preparation, and bioinformatics analyses are described and summarized in the SARS-CoV-2 companion in this issue [4].

3. Results

The highly contagious Delta variant of SARS-CoV-2 surged in southern India in the spring of 2021 [5]. Peak numbers necessitated a cessation of elective clinical visits from May 10, 2021 through May 24, 2021. Elective clinical study participation stopped on May 1, 2021 and resumed June 1, 2021. During this time period of sample collection, 106 patients were consented for study participation (Fig. 1).

Demographics of infectious conjunctivitis study participants are summarized in Table 1. The mean age was 39 years old. 37% of study participants were female. Bilateral conjunctivitis was present in 46% of the population (95% confidence interval (CI): 37% to 56%). Only the right eye was affected in 22% (95% CI: 15% to 31%). Signs and symptoms in the left eye only were present in 32% (95% CI: 24% to 41%). The mean duration of ocular symptoms prior to presentation was 6 days (standard deviation: ±3 days). 102 of 106 participants (96%) provided information regarding close contacts. Of this group, 20% (95% CI: 13% to 28%) reported similar symptoms of ocular redness and irritation in family members and/or close contacts. The most commonly reported subjective symptom from participants was tearing, present in 86% (95% CI: 78% to 91%). Itching was the next most common symptom, presented in 71% (95% CI: 61% to 79%). Purulent discharge was reported in 58% (95% CI: 48% to 67%).

Upon examination, a membranous conjunctivitis (differentiation between membranes and pseudo-membranes was not required) was present in 22% (95% CI: 15% to 31%) of all participants. Slit lamp examination demonstrated corneal sub-epithelial infiltrates in 10% (95% CI: 6% to 18%). 103 of 106 participants (96%) provided information regarding close contacts. Of this group, 20% (95% CI: 13% to 28%) reported similar symptoms of ocular redness and irritation in family members and/or close contacts. The most commonly reported subjective symptom from participants was tearing, present in 86% (95% CI: 78% to 91%). Itching was the next most common symptom, presented in 71% (95% CI: 61% to 79%). Purulent discharge was reported in 58% (95% CI: 48% to 67%).

Table 1

| Demographics, Signs, and Symptoms of Patients Presenting with Presumed Infectious Conjunctivitis During the Delta Variant Surge in Madurai, India. |
|---------------------------------|-----------------|-----------------|
| Gender                          | n = 106         | % (95% CI)      |
| Female                          | 39              | 37 (28, 46)     |
| Male                            | 67              | 63 (54, 72)     |
| Age Years                       | 39 ± 16         |                 |
| Both Eyes Affected              | Yes             | 49              |
| Duration of Symptoms Days       | 6 ± 3           | 46 (37, 56)     |
| Contacts affected               | Yes             | 20              |
| Ocular symptoms                 | Tearing         | 91              |
|                                 | Itching         | 75              |
|                                 | Purulence       | 61              |
| Exam findings                   | Sub-epithelial infiltrates | 11 |
|                                 | Membranes       | 23              |
|                                 | Preauricular adenopathy | 39 |

Plus-minus values are mean ± standard deviation.
95% Confidence intervals were calculated by an Adjusted Wald method.
*Preauricular adenopathy was evaluated in 103 of 106 participants.
participants were using one or more medicated eye drops upon enrollment. Of those using medicated drops, 89% presented on antibacterial drops, (95% CI: 79% to 95%), and 20% (95% CI: 12% to 32%) were using a steroid drop. Anti-fungal, anti-viral and antihistamine drops were each used by 2% (95% CI: 0% to 9%).

In all patients with presumed infectious conjunctivitis, RNA-seq analysis identified an associated pathogen in 88% of cases. The most common pathogen identified (Fig. 2) was human adenovirus species D (HAdV-D), present in 75% (95% CI: 65% to 82%) of cases. The second most common pathogen recovered was SARS-CoV-2, presented in 11% (95% CI: 6% to 19%). *Vittaforma corneae* (microsporidia) was detected in 8% (95% CI: 4% to 15%). Epstein-Barr Virus (EBV) was detected in two cases. Aspergillus and human coronavirus OC43 were each identified as pathogens in 1 case, representing 1% of all cases (95% CI: 0% to 6%). Co-infection, samples meeting definitional criteria for more than one associated organism of conjunctivitis, was present in 7 participants. Additional details describing the coinfection cases are presented in the companion paper.

4. Discussion

The overall effects of the novel COVID-19 pandemic on the frequency, etiologies, and geographic variability of worldwide, recurrent, and seasonal conjunctivitis epidemics are unknown. With the onset of the COVID-19 pandemic, circulation of other respiratory viruses, in and seasonal conjunctivitis epidemics are unknown. With the onset of the timeline and prevalence of typical pathogen reemergence varied based on geography and season[11,12]. In this study, we demonstrate human adenovirus, specifically type 54, was still the most common etiology of infectious conjunctivitis in Madurai, India during the months that corresponded to the Delta surge of COVID-19. SARS-CoV-2, however, was the second most common associated etiology. There were no clear clinical distinguishing features between the two and they can occur together as a co-infection. Pathogens vary by location and continued surveillance is required to determine how and if the frequency of conjunctivitis pathogens change with time.

5. Limitations

54% of all participants were using an antibacterial drop at the time of sample collection. This may be the reason why no bacterial conjunctivitis pathogens were identified. However, this also emphasizes the overuse of topical antibiotics for infectious conjunctivitis which may be predominantly viral in etiology. Additionally, the pathogens identified on the clinical swabs are suggestive for symptom causality, however comparative control swabs from unaffected patients were not obtained so an analysis of comparative risk of disease could not be assessed.

6. Conclusions

This study emphasizes the importance of repeated regional and seasonal surveillance of causes of infectious diseases. The unbiased nature of deep sequencing allows for the detection of unanticipated pathogens and unexpected co-infections. RNA sequencing may be a useful diagnostic tool for the comprehensive surveillance of all viruses, including the RNA virus SARS-CoV-2, that can cause conjunctivitis.

Funding

Research reported in this manuscript was supported by the National Eye Institute of the National Institutes of Health under Award Number R01EY032041 (T.D.), a Research to Prevent Blindness Unrestricted Grant, and the Peierls Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Non-author contribution

Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes (SCORPIO) Study Group

Aravind Eye Hospital, Madurai, India – Lalitha Prajna, N. Venkatesh Prajna, Ramesh Gunasekaran, Sankalp Singh Sharma, Vishnu Teja; B.P Koivala Lions Center for Ophthalmic Studies, Kathmandu, Nepal – Meenu Chaudhary, Sanjeeta Sitaula; centre de Recherche en Sante de Nouna, Nouna, Burkina Faso – Ali Sié, Boubacar Coulibaly, Mamadou Bountogo; Chulalongkorn University, Bangkok, Thailand – Thanapong Somkijrungroj, Vannarut Satitpitakul; Hai Yen Vision Institute, Ho Chi Minh City, Vietnam – Huy Tran, Linh Hoang Mai, Thảo Hsad Luan, Yen Tran; Hospital
New Mexico

Yeh, Steven; Fashina, Tolulope; Nebraska Medical Center Truhlsen Eye Institute, Omaha, Nebraska, USA

California, USA

McLeod; Kevin Ruder, Lina Zhong, Michael Deiner, Thomas Abraham, Thomas

ovation – Anthony W. Solomon

Declaration of Competing Interest

None.

References

[1] C.H. Chang, K.H. Lin, M.M. Sheu, et al., The change of etiological agents and clinical signs of epidemic viral conjunctivitis over an 18-year period in southern Taiwan, Graefes Arch. Clin. Exp. Ophthalmol. 241 (7) (2003) 554-560.

[2] A. Sié, A. Diarra, O. Millogo, et al., Seasonal and temporal trends in childhood conjunctivitis in Burkina Faso, Am. J. Trop. Med. Hyg. 99 (1) (2018) 229-232.

[3] M.S. Deiner, S.D. McLeod, J. Wong, et al., Google searches and detection of conjunctivitis epidemics worldwide, Ophthalmology 126 (9) (2019) 1219-1229.

[4] Venkatesh. N Prajna, Prajna Lalitha, Gomuganta Vishnu Teja, Rameshkumaran Gunasekaran, Sankalp S. Sharma, Armin Hinterwirth, Kevin Ruder, Lina Zhong, Cindi Chen, Michael Deiner, Chih-Hsiong Huang, Benjamin A. Pinsky, Thomas M. Lietman, Gerami D. Seitzman, Thuy Doan, Outpatient human coronavirus associated conjunctivitis in India, Journal of Clinical Virology, Volume 157, 2022.

[5] A.E. Rosato, M. Mubia, B. Weng, et al., Rapid detection of the widely circulating B.1.617.2 (Delta) SARS-CoV-2 variant [published online ahead of print, 2022 Jan 31], Pathology S0031-3025 (22) (2022) 00035–00036, https://doi.org/10.1016/j.pathol.2022.01.001.

[6] K.Y. Park, S. Seo, J. Han, J.Y. Park, Respiratory virus surveillance in Canada during the COVID-19 pandemic: an epidemiological analysis of the effectiveness of pandemic-related public health measures in reducing seasonal respiratory viruses test positivity, PLoS ONE 16 (6) (2021 Jun 18).

[7] M.N. Bouchez, A. Dearte, C.V.C. Palamin, et al., Frequency of respiratory pathogens other than SARS-CoV-2 detected during COVID-19 testing, Diagn. Microbiol. Infect. Dis. 102 (2) (2022), 115576.

[8] J.M. Lavista Forres, T. Meirick, W. Lomazow, C.S. Lee, A.Y. Lee, M.D Lee, pandaemic-related public health measures in reducing seasonal respiratory viruses test positivity, PLoS ONE 16 (6) (2021 Jun 18).

[9] M.S. Deiner, G.D. Seitzman, S.D. McLeod, et al., Ocular signs of COVID-19 suggested by internet search term patterns worldwide, Ophthalmology 128 (1) (2021) 107-109, https://doi.org/10.1016/j.ophtha.2020.06.026.

[10] S.J. Olsen, A.K. Winn, A.P. Budd, et al., Changes in influenza and other respiratory virus activity during the COVID-19 pandemic – United States, 2020-2021, MMWR Morb. Mortal. Wkly. Rep. 70 (2021) 103-1019.

[11] J.A. Mott, A.M. Fry, R. Kondor, et al., Re-emergence of influenza virus circulation during 2020 in parts of tropical Asia: implications for other countries, Influenza Other Respir. Viruses 15 (2021) 415–418.

[12] S. Yum, K. Hong, S. Sohn, et al., Trends in viral respiratory infections during COVID-19 pandemic, South Korea, Emerging Infect. Dis. 27 (6) (2021) 1685–1688.

[13] Retrieved March 20,2022 from https://coronavirus.jhu.edu/map.html.